FDA Sets Review Clock for KEBILIDI Drug Patent Extension Purposes
Published Date: 2/13/2026
Notice
Summary
The FDA has set the official review period for KEBILIDI, a human biological product, so its patent holder can apply for extra patent time. This helps the company protect their invention longer, potentially affecting when generic versions can enter the market. If anyone thinks the dates are wrong or the company wasn’t diligent, they have until April or August 2026 to speak up.
Analyzed Economic Effects
5 provisions identified: 3 benefits, 1 costs, 1 mixed.
FDA Sets 1,612-Day Review Period
The FDA determined the regulatory review period for KEBILIDI is 1,612 days in total, with 1,368 days in the testing phase and 244 days in the approval phase. This determination establishes the maximum potential length of a patent extension that the patent holder may seek from the USPTO.
Applicant Requests Specific Extension Days
In its patent extension application to the USPTO, the applicant for KEBILIDI seeks either 277 days or 816 days of patent term extension. The USPTO will apply statutory limitations when calculating any actual extension.
Possible Delay to Generic Market Entry
The FDA notice states the determination lets the patent holder apply for extra patent time, which can protect the invention longer and potentially affect when generic versions can enter the market. That timing can influence when patients and purchasers may see generic alternatives.
FDA Identifies Key IND/BLA Dates
FDA records show the IND effective date for KEBILIDI was June 17, 2020 (the applicant claimed March 29, 2020), the biologics license application was initially submitted on March 15, 2024, and the application was approved on November 13, 2024. These specific dates were used to derive the testing and approval phase lengths that underlie the regulatory review period.
Deadlines to Challenge Dates or Diligence
Anyone who believes the published dates are incorrect must ask for a redetermination by April 14, 2026. Any interested person may petition FDA regarding whether the applicant acted with due diligence during the regulatory review period by August 12, 2026.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-10321 — Vaccines and Related Biological Products Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments-Safety and Effectiveness of MFLUSIVA (Influenza Vaccine, mRNA) Manufactured by Moderna TX Inc.
The FDA is holding a public meeting on June 18, 2026, to talk about the safety and effectiveness of MFLUSIVA, a new flu vaccine made by Moderna. Anyone can watch online and share their thoughts before June 17. This is a big deal for people who get flu shots and could affect how this vaccine is used and approved.
2026-10295 — M11 Clinical Electronic Structured Harmonised Protocol (CeSHarP); International Council for Harmonisation; Guidance for Industry; Availability
The FDA just released a new, easy-to-use digital guide called M11 CeSHarP to help everyone involved in clinical trials share and review study plans faster and clearer. This affects drug companies, researchers, and regulators worldwide by setting a global standard for how trial info is written and shared electronically. The new rules kick in now, aiming to save time and reduce confusion, with no direct cost but big efficiency gains.
2026-10277 — Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability
The FDA just released new draft guides to help drug makers design studies proving their generic drugs work like the originals. If you’re in the drug business, now’s your chance to share feedback by July 21, 2026, before these guides become final. These updates aim to speed up drug approvals, potentially saving time and money for companies and patients alike!
2026-10284 — Protein Efficiency Ratio Rat Bioassay Studies To Demonstrate That a New Infant Formula Supports the Quality Factor of Sufficient Biological Quality of Protein; Guidance for Industry; Availability
The FDA just released new guidance to help baby formula makers prove their products have good-quality protein using special rat studies. This update affects formula manufacturers and labs, making it easier and clearer to show their formulas meet nutrition standards. The guidance is effective now, helping companies avoid costly mistakes and speed up getting new formulas to market.
2026-10268 — Notice of Decision Not To Designate Hepatitis Delta Virus Diseases as an Addition to the Current List of Tropical Diseases in the Federal Food, Drug, and Cosmetic Act
The FDA decided not to add Hepatitis Delta Virus (HDV) to the list of tropical diseases because it doesn’t fully meet the rules about market size and who it affects. This means drug makers won’t get special priority review vouchers for HDV treatments right now. People working on HDV drugs should keep an eye out for future updates but won’t see changes or new incentives immediately.
2026-10190 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Patent Term Restoration; Due Diligence Petitions; Filing, Format, and Content of Petitions
The FDA is updating how companies ask for extra patent time when their new drugs or devices take a while to get approved. This affects drug and medical device makers who want to protect their inventions longer. Comments on these changes are open until June 22, 2026, and the update aims to keep the process clear without adding extra costs or delays.
Previous / Next Documents
Previous: 2026-02974 — Determination of Regulatory Review Period for Purposes of Patent Extension; AMTAGVI
The FDA has officially set the review period for AMTAGVI, a new human biological product, so its patent can be extended. This affects the company behind AMTAGVI and anyone interested in patent timing or drug availability. If you think the dates are wrong or want to challenge the company’s diligence, you have until April 14 or August 12, 2026, to speak up—so don’t miss these deadlines!
Next: 2026-02977 — Agency Forms Submitted for OMB Review, Request for Comments
The Railroad Retirement Board is asking for public feedback on forms used to prove marriage status for railroad benefits. They want to make sure the forms are clear, useful, and not too much work to fill out. If you’re involved in railroad benefits, your input can help shape these forms—comments are due within 30 days, so don’t miss out!